

## **Patent claims**

1. Therapeutic agent for the treatment of septicemia containing the protein binding lipopolysaccharide (LBP), its variants, mutants or hybrid proteins
2. Agent according to claim 1 containing human LBP
3. Agent according to claim 1 containing murine LBP
4. Agent according to claim 1 containing rabbit or rat LBP
5. Agent according to claim 1 containing the hybrid proteins LBP with the LPS binding site of the bactericidal/permeability increasing protein (BPI) or LBP with the LPS binding site of the limulus anti-LPS factor (LALF)
6. Agent according to claim 1 containing point-mutated variants the functions of which are improved in the area of the LPS binding site (amino acids 91-101) by individual exchanges of amino acids
7. Method to produce the agent according to claims 1-6 wherein LBP is expressed in the baculovirus system and in CHO cells, first of all, as fusion protein and then purified by the participant in the fusion by means of separation methods known per se
8. Use of the agent according to claims 1-6a for the therapeutic treatment of septicemia caused by gram-negative bacteria.
9. Use of the agent according to claims 1-6a for the therapeutic treatment of septicemia caused by gram-positive bacteria.
10. Use of the agent according to claims 1-6a for the therapeutic treatment of SIRS caused by trauma and injury.
11. Agent according to claim 1 wherein the LBP gene is cloned in an adenoviral vector behind a strong promoter, preferably the CMV promoter, and subsequently a gene transfer into the affected liver cells is carried out.